



Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

Date: 17th June, 2026

**To,
The Deputy Manager
(Department of Corporate Services),
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400001.**

Sub.: Corrigendum to the Notice of Extra-Ordinary General Meeting to be held on Wednesday, 01st July, 2026 pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”).

**Ref.: Scrip Id: NOVELIX
Scrip Code: 536565**

Ref: Our earlier Intimation dated 09th June, 2026, for Notice of Extra Ordinary General Meeting.

Respected Sir/Madam,

This is in continuation of the Notice of Extra-Ordinary General Meeting of the Company (EGM Notice) to be held on Wednesday, July 01, 2026, at 3.30 P.M. through Video Conferencing (“VC”)/Other Audio-Visual Means (OAVM), notice of which has already been emailed to all the shareholders of the Company on 09th June, 2026. A Corrigendum is being issued today to inform all the Shareholders to whom the Notice of Extra-Ordinary General Meeting has been sent regarding changes in the EGM Notice and Explanatory Statement due to change in Item No. 1. A copy of the detailed Corrigendum is enclosed herewith. The said Corrigendum is also being uploaded on the website of the Company. Except as detailed in the attached Corrigendum, all other items of the EGM Notice, along with the Explanatory Statement shall remain unchanged. This Corrigendum will also be available on the Website of the Company www.novelixpharma.com.

Please note that on and from the date hereof, the EGM Notice dated 04th June, 2026 shall always be read collectively with this Corrigendum.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we kindly request you to take into record the above submissions and the attached Corrigendum.

Thanking you,

Yours faithfully,

For Novelix Pharmaceuticals Limited

**Venkateshwarlu Pulluru
(Whole-time director)
DIN: 02076871**

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com
www.novelixpharma.com



Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

CORRIGENDUM TO THE NOTICE OF EXTRA ORDINARY GENERAL MEETING

We draw attention of all the Members of **NOVELIX PHARMACEUTICALS LIMITED (formerly known as Trimurthi Limited)** (“the Company”) to the Notice dated 04th June, 2026, convening the Extra Ordinary General Meeting (“EGM”) of the Company (“EGM Notice”) scheduled to be held on Wednesday, July 01, 2026, at 3.30 P.M. IST, through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”). The EGM Notice has already been electronically sent to all the members of the Company on Tuesday, 09th June, 2026 whose email addresses were registered with the Company and/ or Depository Participant(s) in compliance with the provisions of the Companies Act, 2013 (“the Act”), the rules made thereunder, and the circulars issued by the Ministry of Corporate Affairs (“MCA”) and the Securities and Exchange Board of India (“SEBI”) (collectively referred to as “Circulars”).

The Company had applied to BSE Limited (BSE) for *in-principle approval* for the issuance of 12,00,000 equity shares on a preferential basis for cash consideration.

During BSE’s review, it was observed that SAKSHI MALANI, (Sr. No. 1 in the resolution), sold 75 shares during 18/02/2026 to 25/02/2026. This sale occurred within 90 trading days preceding the relevant date, violating Regulation 159(1)(c) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR Regulations”). As a result, SAKSHI MALANI is disqualified from receiving shares under the preferential allotment and will not be allotted 1,50,000 equity shares that were proposed to be issued to her.

The Company has decided to re-allocate these 150,000 shares to the existing proposed allottees SUMAN RAJIV BIHANI (Sr. No. 5 in the resolution), VEDANT RAJIV BIHANI (Sr. No. 6 in the resolution) and PRAKASH GALDA (Sr. No. 7 in the resolution) 50,000 equity shares each.

Further PALLAPOTHU SIVAKRISHNA (Sr. No. 18 in the resolution) sold 77 shares during 23/02/2026 to 24/02/2026. This sale also occurred within 90 trading days preceding the relevant date, violating Regulation 159(1)(c) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR Regulations”). As a result, PALLAPOTHU SIVAKRISHNA is disqualified from receiving shares under the preferential allotment and will not be allotted 25,000 equity shares that were proposed to be issued to him.

The Company has decided to re-allocate these 25,000 shares to the existing proposed allottee T PRAVEEN KUMAR (Sr. No. 11 in the resolution).

Accordingly, this Corrigendum to the EGM Notice (“Corrigendum”) is being issued to provide certain clarifications, modifications, and updates to the EGM Notice, pursuant to the observations of BSE, and in accordance with the provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“ICDR Regulations”), the applicable provisions of the Act, the rules made thereunder, and the MCA Circulars.

As the Members are aware, the Company is offering remote e-voting facility to enable the Members to cast their votes on all resolutions proposed to be transacted at the EGM. In order to facilitate informed decision-making, whether through remote e-voting or during the EGM via VC/OAVM, the Company considers it appropriate to bring to the Members’ attention the updated factual position through this Corrigendum.

This Corrigendum shall form an integral part of the original EGM Notice and shall be read in conjunction therewith.

Below are the modifications in the Resolution and Explanatory Statement of Item No.: 01 of the EGM Notice:

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com



Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

1. The details of SAKSHI MALANI under Sr. No. 1 and PALLAPOTHU SIVAKRISHNA under Sr. No. 18 wherever appearing in the Resolution and Explanatory Statement is now deleted.
2. The name of Allottee No. 7, wherever appearing in the Resolution and Explanatory Statement annexed to the Notice, shall be read as 'PRAKASH GALDA' instead of 'PRAKASH GADLA' due to a typographical error. All references to 'PRAKASH GADLA' in the Resolution and Explanatory Statement shall accordingly stand corrected as 'PRAKASH GALDA'.
3. The details of SUMAN RAJIV BIHANI (Sr. No. 5 in the resolution), VEDANT RAJIV BIHANI (Sr. No. 6 in the resolution), PRAKASH GALDA (Sr. No. 7 in the resolution) and T PRAVEEN KUMAR (Sr. No. 11 in the resolution) is now modified and the table in resolution would now be revised as follows:

Sr. No.	Name of the Proposed Allottees	Category (Promoter or Promoter Group / Non Promoter)	No. of Equity Shares proposed to be allotted	Name of the Ultimate Beneficial Owner
1	PEDDI SRIDHAR	Non Promoter	100000	PEDDI SRIDHAR
2	PALAKURTHI RAKESH	Non Promoter	100000	PALAKURTHI RAKESH
3	RAHUL INNANI	Non Promoter	100000	RAHUL INNANI
4	SUMAN RAJIV BIHANI	Non Promoter	100000	SUMAN RAJIV BIHANI
5	VEDANT RAJIV BIHANI	Non Promoter	100000	VEDANT RAJIV BIHANI
6	PRAKASH GALDA	Non Promoter	100000	PRAKASH GALDA
7	K VARSHA	Non Promoter	50000	K VARSHA
8	VIJAYA SURESH NIMBALE	Non Promoter	25000	VIJAYA SURESH NIMBALE
9	PRASANTH SOWMITHRY BRUNDAVANAM	Non Promoter	25000	PRASANTH SOWMITHRY BRUNDAVANAM
10	T PRAVEEN KUMAR	Non Promoter	140000	T PRAVEEN KUMAR
11	ALLADI PRAVEEN	Non Promoter	50000	ALLADI PRAVEEN
12	GANGADHAR KATHURI	Non Promoter	10000	GANGADHAR KATHURI
13	RAJENDER BELIDE	Non Promoter	100000	RAJENDER BELIDE
14	BELIDE VIJAYALAKSHMI	Non Promoter	100000	BELIDE VIJAYALAKSHMI
15	VENKATRAMANA MANUSANI	Non Promoter	50000	VENKATRAMANA MANUSANI
16	MANUSANI JALAJA LAXMI	Non Promoter	50000	MANUSANI JALAJA LAXMI
	TOTAL		12,00,000	

4. Under Explanatory Statement:

- i. Table under Point No. 1 i.e. "List of Allottees for Preferential Allotment of Equity Shares" would now be revised as follows:

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com



Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

Sr. No.	Name of the Proposed Allottees	Category (Promoter or Promoter Group / Non Promoter)	No. of Equity Shares proposed to be allotted	Name of the Ultimate Beneficial Owner
1	PEDDI SRIDHAR	Non Promoter	100000	PEDDI SRIDHAR
2	PALAKURTHI RAKESH	Non Promoter	100000	PALAKURTHI RAKESH
3	RAHUL INNANI	Non Promoter	100000	RAHUL INNANI
4	SUMAN RAJIV BIHANI	Non Promoter	100000	SUMAN RAJIV BIHANI
5	VEDANT RAJIV BIHANI	Non Promoter	100000	VEDANT RAJIV BIHANI
6	PRAKASH GALDA	Non Promoter	100000	PRAKASH GALDA
7	K VARSHA	Non Promoter	50000	K VARSHA
8	VIJAYA SURESH NIMBALE	Non Promoter	25000	VIJAYA SURESH NIMBALE
9	PRASANTH SOWMITHRY BRUNDAVANAM	Non Promoter	25000	PRASANTH SOWMITHRY BRUNDAVANAM
10	T PRAVEEN KUMAR	Non Promoter	140000	T PRAVEEN KUMAR
11	ALLADI PRAVEEN	Non Promoter	50000	ALLADI PRAVEEN
12	GANGADHAR KATHURI	Non Promoter	10000	GANGADHAR KATHURI
13	RAJENDER BELIDE	Non Promoter	100000	RAJENDER BELIDE
14	BELIDE VIJAYALAKSHMI	Non Promoter	100000	BELIDE VIJAYALAKSHMI
15	VENKATRAMANA MANUSANI	Non Promoter	50000	VENKATRAMANA MANUSANI
16	MANUSANI JALAJA LAXMI	Non Promoter	50000	MANUSANI JALAJA LAXMI
	TOTAL		12,00,000	

- ii. Accordingly, Table under Point No. 12 i.e. Identity of the natural persons who are the ultimate beneficial owners of the shares proposed to be allotted and/or who ultimately control the proposed allottees, the percentage of post preferential issues that may be held by them and change in control if any in the issuer consequent to the preferential issues will be revised as follows:

Sr. No.	Name of the Proposed Allottees	Category (Promoter/ Non Promoter)	Ultimate Beneficial Owner	Pre-Preferential Issue*	No. of Equity Shares proposed to be	Post Preferential Issue
---------	--------------------------------	-----------------------------------	---------------------------	-------------------------	-------------------------------------	-------------------------

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com



Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

		Promoter)		No. of Shares held	% of share holding	allotted	No. of Shares held	% of share holding (considering 12,00,000 Equity Shares under current Preferential Issue)	% of share holding (considering 12,00,000 Equity Shares under current Preferential Issue and assuming full conversion of 33,75,000 outstanding warrants allotted on 10th January, 2025 into equity shares.)
1	PEDDI SRIDHAR	Non Promoter	PEDDI SRIDHAR	58399	0.24%	100000	158399	0.63%	0.56%

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com



Novelx Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

2	PALAKURTHI RAKESH	Non Promoter	PALAKURTHI RAKESH	574110	2.40%	100000	674110	2.69%	2.37%
3	RAHUL INNANI	Non Promoter	RAHUL INNANI	0	0.00%	100000	100000	0.40%	0.35%
4	SUMAN RAJIV BIHANI	Non Promoter	SUMAN RAJIV BIHANI	40000	0.17%	100000	140000	0.56%	0.49%
5	VEDANT RAJIV BIHANI	Non Promoter	VEDANT RAJIV BIHANI	40000	0.17%	100000	140000	0.56%	0.49%
6	PRAKASH GALDA	Non Promoter	PRAKASH GALDA	50000	0.21%	100000	150000	0.60%	0.53%
7	K VARSHA	Non Promoter	K VARSHA	0	0.00%	50000	50000	0.20%	0.18%
8	VIJAYA SURESH NIMBALE	Non Promoter	VIJAYA SURESH NIMBALE	0	0.00%	25000	25000	0.10%	0.09%
9	PRASANTH SOWMITHRY BRUNDA VANAM	Non Promoter	PRASANTH SOWMITHRY BRUNDA VANAM	0	0.00%	25000	25000	0.10%	0.09%
10	T PRAVEEN KUMAR	Non Promoter	T PRAVEEN KUMAR	50245	0.21%	140000	190245	0.76%	0.67%
11	ALLADI PRAVEEN	Non Promoter	ALLADI PRAVEEN	42041	0.18%	50000	92041	0.37%	0.32%
12	GANGADHAR KATHURI	Non Promoter	GANGADHAR KATHURI	0	0.00%	10000	10000	0.04%	0.04%
13	RAJENDER BELIDE	Non Promoter	RAJENDER BELIDE	50000	0.21%	100000	150000	0.60%	0.53%
14	BELIDE VIJAYALAKSHMI	Non Promoter	BELIDE VIJAYALAKSHMI	50000	0.21%	100000	150000	0.60%	0.53%
15	VENKATRAMANA MANUSANI	Non Promoter	VENKATRAMANA MANUSANI	200000	0.84%	50000	250000	1.00%	0.88%

Novelx Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com



Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

16	MANUSANI JALAJA LAXMI	Non Promoter	MANUSANI JALAJA LAXMI	100000	0.42%	50000	150000	0.60%	0.53%
----	-----------------------------	--------------	-----------------------------	--------	-------	-------	--------	-------	-------

* As on 29th May, 2026

iii. Accordingly, Table under Point No. 13 i.e. The Current and Proposed status of the allottees post the preferential issue namely, promoter or non-promoter will be revised as follows:

Sr. No.	Name of the Proposed Allottees	Current status of the allottees namely promoter or non-promoter	Proposed status of the allottees post the preferential issue namely promoter or non-promoter
1	PEDDI SRIDHAR	Non Promoter	Non Promoter
2	PALAKURTHI RAKESH	Non Promoter	Non Promoter
3	RAHUL INNANI	Non Promoter	Non Promoter
4	SUMAN RAJIV BIHANI	Non Promoter	Non Promoter
5	VEDANT RAJIV BIHANI	Non Promoter	Non Promoter
6	PRAKASH GALDA	Non Promoter	Non Promoter
7	K VARSHA	Non Promoter	Non Promoter
8	VIJAYA SURESH NIMBALE	Non Promoter	Non Promoter
9	PRASANTH SOWMITHRY BRUNDAVANAM	Non Promoter	Non Promoter
10	T PRAVEEN KUMAR	Non Promoter	Non Promoter
11	ALLADI PRAVEEN	Non Promoter	Non Promoter
12	GANGADHAR KATHURI	Non Promoter	Non Promoter
13	RAJENDER BELIDE	Non Promoter	Non Promoter
14	BELIDE VIJAYALAKSHMI	Non Promoter	Non Promoter
15	VENKATRAMANA MANUSANI	Non Promoter	Non Promoter
16	MANUSANI JALAJA LAXMI	Non Promoter	Non Promoter

With effect from the date of this Corrigendum, the EGM Notice shall always be read in conjunction with this Corrigendum which is also being uploaded on the website of the Company at www.novelixpharma.com and on the website of CDSL at www.evotingindia.com, and Stock Exchanges i.e. www.bseindia.com.

All other contents of the EGM Notice, save and except as amended / clarified by this Corrigendum, shall remain unchanged.

**By the order of the Board of Directors
For Novelix Pharmaceuticals Limited**

Date: 17th June, 2026

Place: Hyderabad

Sd/-
Venkateshwarlu Pulluru
(Whole Time Director)
DIN: 02076871

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com